

Supplemental Table 4

Baseline demographics of patients with MINOCA versus MI with obstructive coronary artery disease grouped according to the assigned clopidogrel-dosing regimens

	Overall (n= 23,783)	MINOCA (n= 1,599)		<i>p</i> -value*	MI with obstructive CAD (n= 22,184)		<i>p</i> -value*
		Standard clopidogrel dosing (n=785)	Double clopidogrel dosing (n=814)		Standard clopidogrel dosing (n=11172)	Double clopidogrel dosing (n=11012)	
Age (years)	61.5±11.9	58.2±14.9	57.1±13.5	0.1018	61.8±11.6	61.7±11.7	0.6787
Males (%)	17519 (73.7)	407 (51.8)	444 (54.5)	0.280	8378 (75.0)	8290 (75.3)	0.617
<i>Presentation:</i>							
NSTEMI	7137 (30.0)	728 (92.7)	730 (89.7)	0.031	7657 (68.5)	7531 (68.4)	0.812
STEMI	16646 (70.0)	57 (7.3)	84 (10.3)	0.031	3515 (31.5)	3481 (31.6)	0.812
Heart failure at presentation	2001 (8.4)	50 (6.4)	58 (7.1)	0.547	954 (8.5)	939 (8.5)	0.974
Grace Score	122.9±28.8	113±28	113±28	0.7828	123±28	124±29	0.2341
Heart rate at presentation (bpm)	74±14	75±14	74±14	0.5258	74±14	74±14	0.4491
Systolic BP at presentation (mmHg)	134±22	133±22	132±21	0.1580	135±22	134±22	0.023
Diastolic BP at presentation (mmHg)	79±13	78±13	77±13	0.3166	79±13	79±13	0.159
Left ventricular ejection fraction (%)	53±14	56±14	56±14	0.8995	52±14	53±14	0.5674
Diabetes mellitus (%)	5602 (23.6)	131 (16.7)	97 (11.9)	0.006	2691 (24.1)	2683 (24.4)	0.632
Hypertension (%)	14349 (60.3)	434 (55.3)	444 (54.5)	0.766	6782 (60.7)	6689 (60.8)	0.941
Dyslipidaemia (%)	9833 (41.4)	293 (37.3)	283 (34.8)	0.287	4651 (41.6)	4606 (41.8)	0.758
Family history of premature CAD (%)	5438 (22.9)	175 (22.3)	173 (21.3)	0.623	2567 (23.0)	2523 (22.9)	0.879
Smokers (%) [†]	8056 (33.9)	188 (23.9)	208 (25.6)	0.449	3827 (34.3)	3833 (34.8)	0.374
Previous MI (%)	4333 (18.2)	64 (8.2)	72 (8.8)	0.620	2095 (18.8)	2102 (19.1)	0.523
Previous PCI (%)	3561 (15.0)	60 (7.6)	59 (7.2)	0.763	1727 (15.5)	1715 (15.6)	0.812
Previous Stroke (%)	976 (4.1)	15 (1.9)	17 (2.1)	0.800	483 (4.3)	461 (4.2)	0.613
Peripheral arterial disease (%)	1142 (4.8)	19 (2.4)	16 (2.0)	0.534	552 (4.9)	555 (5.0)	0.735
Cancer (%)	1024 (4.3)	28 (3.6)	33 (4.1)	0.611	492 (4.4)	471 (4.3)	0.643
<i>Antithrombotics prior to randomization (%)</i> :							
Aspirin	9464 (39.8)	269 (34.3)	261 (32.1)	0.349	4503 (40.3)	4431 (40.2)	0.922
Clopidogrel	5201 (21.9)	125 (15.9)	165 (20.3)	0.024	2463 (22.0)	2448 (22.2)	0.744
Unfractionated heparin	17832 (75.0)	264 (33.6)	270 (33.3)	0.872	8702 (77.9)	8596 (78.1)	0.751
LMWH	12107 (50.9)	391 (49.8)	394 (48.5)	0.607	5662 (50.7)	5660 (51.4)	0.285

Fondaparinux	1153 (4.8)	47 (6.0)	48 (5.9)	0.944	540 (4.8)	518 (4.7)	0.652
Bivalirudin	958 (5.6)	1 (4.0)	2 (7.4)	0.599	477 (5.5)	478 (5.6)	0.764
GP IIb/IIIa inhibitors	7874 (33.1)	85 (10.8)	95 (11.7)	0.582	3852 (34.5)	3842 (34.9)	0.524
Fibrinolytics †	725 (10.2)	14 (24.6)	13 (15.5)	0.178	356 (10.1)	342 (9.8)	0.672
<i>Other medication (%):</i>							
β-blockers	18924 (80.2)	475 (60.7)	499 (61.6)	0.724	9037 (81.5)	8913 (81.7)	0.754
Ca-channel blockers	14879 (63.1)	154 (19.7)	166 (20.5)	0.690	1505 (13.6)	1460 (13.4)	0.671
ACE-inhibitors	2337 (9.9)	377 (48.2)	379 (46.8)	0.571	7126 (64.3)	6997 (64.2)	0.822
AT-2-antagonists	3285 (13.9)	78 (10.0)	86 (10.6)	0.673	1102 (9.9)	1071 (9.8)	0.753
Diuretics	4933 (20.9)	149 (19.1)	159 (19.6)	0.771	2307 (20.8)	2318 (21.3)	0.429
Nitrates	850 (3.6)	17 (2.2)	21 (2.6)	0.584	409 (3.7)	403 (3.7)	0.990
Statins	20581 (87.3)	537 (68.7)	550 (67.9)	0.742	9824 (88.6)	9670 (88.7)	0.996
Other lipid lowering agents	1403 (6.0)	33 (4.2)	36 (4.4)	0.826	700 (6.3)	634 (5.8)	0.117
NSAIDs	1938 (8.2)	35 (4.5)	37 (4.6)	0.929	491 (4.4)	467 (4.3)	0.588
Insulin	3716 (15.8)	25 (3.2)	24 (3.0)	0.787	967 (8.7)	922 (8.5)	0.466
Oral hypoglycaemic agents	1030 (4.4)	98 (12.5)	58 (7.2)	<0.0001	1781 (16.1)	1779 (16.3)	0.634
Proton Pump Inhibitors	5189 (29.9)	136 (25.7)	149 (27.0)	0.619	2468 (30.0)	2436 (30.2)	0.855
<i>Antiplatelets after randomization (%):</i>							
Higher-dose ASA	11850 (49.8)	371 (47.3)	422 (51.8)	0.067	5577 (49.9)	5480 (49.8)	0.817
Lower-dose ASA	11933 (50.2)	414 (52.7)	392 (48.2)	0.067	5595 (50.1)	5532 (50.2)	0.817
<i>Baseline laboratories:</i>							
Platelets (x 10 ⁹ /L)	232 (194; 276)	240 (200; 290)	241 (201; 289)	0.7695	231 (193; 275)	232 (194; 276)	0.2553
Hemoglobin (g/dL)	14.0±1.7	13.9±1.6	13.9±1.7	0.1186	14.1±1.7	14.0±1.7	0.7897
WBC (x 10 ⁹ /L)	9.6±3.6	8.9±3.3	9.1±3.4	0.3925	9.7±3.6	9.7±3.7	0.7288
Creatinine clearance (mL/min)	80.9±26.2	84±27	84±27	0.9124	81±26	81±26	0.9493
Creatinine (μmol/L)	89.7±26.1	83±24	85±26	0.2518	90±26	90±26	0.5482
Troponin I (μg/L)	0.5 (0.1-2.3)	0.6 (0.2; 2.1)	0.5 (0.1; 2.1)	0.2190	0.5 (0.1; 2.5)	0.5 (0.1-2.3)	0.3477
Troponin T (μg/L)	0.1 (0.0-0.4)	0.2 (0.1; 0.5)	0.1 (0.0; 0.3)	0.0021	0.1 (0.0; 0.5)	0.1 (0.0; 0.4)	0.7162
CK-MB (U/L)	22 (12-45)	24 (14; 39)	25 (14; 40)	0.4715	22 (12; 46)	22 (12; 45)	0.5636
CK-MB (%)	11 (6-16)	12 (7.0; 21.0)	13 (7- 19)	0.9735	11.0 (6.0; 16.0)	11.0 (6.0; 16.0)	0.9770
Total CK (U/L)	155 (88-336)	157 (94; 291)	164 (92; 301)	0.9874	154 (88; 341)	154 (87; 339)	0.929
<i>Stents (%):</i>							
Bare metal stents (only)	9448 (39.7)	12 (66.7)	15 (68.2)	0.919	4751 (58.0)	4670 (57.9)	0.877
Drug eluting stents	6857 (28.8)	6 (33.3)	7 (31.8)	0.919	3443 (42.0)	3401 (42.1)	0.877

<i>Vessels with CAD:</i>							
Left main	330 (1.9)	-	-	-	156 (1.89)	174 (2.0)	0.248
1-vessel disease	13204 (76.6)	-	-	-	6654 (76.8)	6550 (76.9)	0.904
2-vessel disease	2365 (13.7)	-	-	-	1202 (13.9)	1163 (13.7)	0.671
3-vessel disease	1111 (6.4)	-	-	-	556 (6.4)	555 (6.5)	0.797
Saphenous vein / arterial graft	479 (2.8)	-	-	-	226 (2.6)	253 (3.0)	0.151
Visible angiographic thrombus before PCI	5459 (32.8)	9 (37.5)	14 (53.8)	0.247	2736 (32.7)	2700 (32.8)	0.926

Data are mean (standard deviation), median (interquartile range) or number (percentage), as appropriate. BP = Blood pressure; CAD = Indicates coronary artery disease; GP IIb/IIIa inhibitors = Glycoprotein IIb/IIIa inhibitors; LMWH = Low molecular weight heparin; MI = Myocardial infarction; MINOCA = Myocardial infarction with no obstructive coronary artery disease; NSTEMI = Non-ST-segment elevation myocardial infarction; PCI = Percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; WBC = White blood cell count.

* P values were based on student's t-tests or Mann-Whitney U- tests, as appropriate.

† Smokers were classified as current smokers.

‡ As initial reperfusion strategy,